Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

PET in Theranostics: Patient Selection, Treatment Planning, and Response Assessment.

Created on 30 Oct 2026

Authors

Eren Veziroglu, Mahsa Gifani, Moozhan Nikpanah, Vrushab Gowda, Faraz Farhadi, Babak Saboury

Published in

Radiologic clinics of North America. Volume 64. Issue 6. Pages 1127-1144.

Abstract

Theranostics pairs molecular imaging with a therapeutic radiopharmaceutical directed at the same target, with PET assessing target expression, disease extent, interlesional heterogeneity, and FDG discordance. Three established applications are reviewed: PSMA PET-guided selection for lutetium-177-PSMA-617 in metastatic androgen pathway modulation-resistant prostate cancer, somatostatin receptor PET-guided peptide receptor radionuclide therapy in neuroendocrine tumors, and iodine-124/FDG PET within radioiodine therapy for differentiated thyroid cancer. Practical guidance covers patient selection, image interpretation, treatment planning, response assessment, and reporting. A key paradigm: diagnostic uptake confirms target availability but neither measures delivered dose nor guarantees response; biomarkers, dosimetry, and response frameworks remain variably validated.

PMID:
42957400
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement